Abivax to host key opinion leader (kol) webcast on march 17, 2025

Abivax to host key opinion leader (kol) webcast on march 17, 2025 event to feature renowned gastroenterologist dr. david rubin, highlighting the ulcerative colitis treatment landscape and abivax's pivotal abtect phase 3 trial paris, france – february 21, 2025 – 8:30 am cet – abivax sa (euronext paris: fr0012333284 – abvx / nasdaq: abvx) (“abivax” or the “company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a key opinion leader (kol) investor webcast on monday, march 17, 2025, at 9:00 a.m. edt (2:00 p.m.
ABVX Ratings Summary
ABVX Quant Ranking